Table 3 COVID-19 patients’ characteristics.
From: ACE2 polymorphisms impact COVID-19 severity in obese patients
COVID-19 subjects characteristics | ||
|---|---|---|
Parameters | Lean | Obese/overweight |
Subjects (N) | 35 | 47 |
Age (years) | 42 ± 15 | 50 ± 16 |
Gender, M/ F | 22/13 | 38/9 |
BMI (kg/m2) | 22 ± 2 | 30 ± 4 |
Serum markers | ||
AST (U/L) | 28.5 (393–3.2) | 31 (660–12) |
ALT (U/L) | 33 (660–3.2) | 32 (659–6) |
Hb (g/dL) | 13.25 (15.7–7) | 12.9 (16.8–7) |
ALC | 1.4 (3.1–0.2) | 1.4 (4.6–0.3) |
Creatinine (mg/dL) | 0.9 (7.9–0.2) | 0.8 (2.6–0.4) |
Ferritin (µg/L) | 505 (5147–5) | 669 (6661–38) |
aPTT (sec) | 38.5 (63.2–31.8) | 40.25 (64.7–31.9) |
BUN (mg/dL) | 28 (134–9.3) | 27.5 (269–8) |
WBC (k/cumm) | 7.6 (16.7–3.1) | 8 (25.4–4.2) |
Platelets (× 103/ L) | 219 (456–62) | 237.5 (592–91) |
LDH (units/L) | 268 (925–137) | 283 (1719–140) |
Bilirubin (µmol/L) | 0.7 (48.2–0.2) | 0.7 (11.2–0.2) |
Medication (%) | ||
Metformin, Diamicron, Statins, Insulin | 5% | 46% |
Plavix, Aspirin | 3% | 11% |
Nationality (%) (Geographical zones) | ||
Middle East | 3% | 9% |
Eastern and Southern Asia | 35% | 49% |
Northern and Southern America | 1% | 2% |
Africa | 1% | – |
